Is Alzheimer's Research the Next Big Thing in Biotech?

The biotechnology sector is well known for companies chasing the latest hot trend. In the early 2000s it was genome mapping technologies, while more recently we've seen investing dollars streaming into hepatitis-C research. Chasing a hot trend isn't a bad thing as it's usually resulted in improvements in patient care; cheaper genome sequencing and a myriad of non-interferon-based hepatitis-C drug hopefuls are a good example of this in action.

With numerous other popular routes for investment dollars to go next, including RNAi pathway drugs and antibody-drug conjugates, I actually feel that Alzheimer's research represents the next logical area of focus for biotechnology companies.

Research firm Decision Resources predicted last year that the market value of Alzheimer's drugs could nearly triple to $14.3 billion from $5.4 billion by 2020, leaving plenty of room for growth and innovation -- especially for big pharmaceutical companies whose pipelines are lacking organic growth.

The current state of the Alzheimer's drug market is fractured at best. The few FDA-approved drugs currently approved to treat Alzheimer's are either losing ground to generic competition, readying to lose patent exclusivity, or come complete with a laundry list of negative side effects. Eisai's Aricept has found the going tough with generic competition beefing up in the U.S., while Forest Labs' (NYSE: FRX  ) Namenda is slated to lose its patent exclusivity in 2015.

Clinical trial failures have also been commonplace in recent months. A lot of that has to do with the simple fact that the blood-brain barrier is difficult to penetrate with medicine, so developing an effective and safe drug is both time consuming and difficult. There have been a few notable trials recently that ended in FDA defeat, including bapineuzumab, which was developed by Johnson & Johnson (NYSE: JNJ  ) and Pfizer (NYSE: PFE  ) , as well as solanezumab, developed by Eli Lilly (NYSE: LLY  ) .

But promise still remains for the sector as a whole, as is evidenced by yesterday's announcement that investigational scientists are undertaking three international long-term drug studies on the prevention of Alzheimer's by examining three beta amyloid-targeting drugs. Of the 15 drug hopefuls submitted for the study, scientists chose two from Eli Lilly, solanezumab, which attaches to amyloid floating free in the brain before it attaches and becomes plague, and LY2886721, which blocks the beta-secretase enzyme used to make amyloid, as well as one drug from Roche (NASDAQOTH: RHHBY  ) , gantenerumab, that binds to clumps of amyloid and allows it to be removed from the brain.

The studies are slated to start next year and will actually target those who are genetically destined to get the disease, but are showing little to no degenerative decline from Alzheimer's. The goal over a two year period is to determine if one of the three drugs offers a clinical benefit over the other two in preventing Alzheimer's from developing, and if so, to switch all patients to that drug and study its long-term effects.

It appears clear to me that Alzheimer's is the next big money area for biotech and big pharma as patient needs are still largely unmet and prevalence of the disease is on the rise. Keep your eyes on these stocks moving forward as they could wind up being in the center of the next hottest trend in biotech.

Just as the biotech sector is searching for the next breakthrough therapy, our analysts at Stock Advisor are tirelessly scouring the market looking for the next revolutionary technology -- and they just may have found it! Click here for free access to our latest special report that highlights three companies they feel have a unique technology that could transform the sector.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 11, 2012, at 1:26 PM, trrll wrote:

    Alzheimer's treatments are the next big thing--IF anybody manages to come up with one that works better than the present marginally-effective medications. So far, the results have been disappointing. Treatments designed to remove beta-amyloid from the brain don't make Alzheimer's patients appreciably better, or even slow the course of the disease. This is a real challenge to theory. The only bright spot is that for some of the new drugs, there is a hint of benefit in the mildest cases (using a statistically-questionable reanalysis). So there are two possibilities:

    1) The beta-amyloid theory of Alzheimer's Disease is all wrong, or at least wrong for the great majority of cases without a clear genetic cause. Perhaps beta-amyloid accumulation is a consequence of damage rather than a cause. In this case, all bets are off, and we're nearly back to square one (and nobody is going to be making big bucks off Alzheimer's treatments in the near future).

    2) The beta-amyloid theory is only partly wrong. Perhaps beta-amyloid is important only in the very early stages of the disease before clear clinical symptoms emerge, but after that point the damage is done, at least as far as beta-amyloid is concerned--brain damage continues to accumulate via other mechanisms. If this turns out to be true, then treatment will hinge on improved methods of early diagnosis (which look promising), so that beta-amyloid based therapies can be applied early enough to make a difference. However, the bar for such therapies will be raised, because instead of treating people who are already seriously ill (and for whom a moderate risk of adverse effects is acceptable), we'll be treating people who are still mostly OK, but who are likely to develop Alzheimer's Disease at some point in the future (so we'll need very safe treatments).

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2053327, ~/Articles/ArticleHandler.aspx, 10/21/2014 4:55:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement